PROSPECTIVE DIRECTIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE
Keywords:
chronic heart failure, pathogenetic treatmentAbstract
The high incidence (1-2%) of the population of chronic heart failure (CHF), an increase in the average age of newly diagnosed patients, a progressive course, the need for inpatient treatment, and an unfavorable prognosis determine the relevance and need for further study of this pathological syndrome. This article discusses new successful directions of pharmacological and non-drug correction of cardiac dysfunction in the treatment of patients with CHF, many changes that can be described as evolutionary in the problem of heart failure, ways to improve the quality of life, and life expectancy of patients with CHF.
References
Lawson CA, Zaccardi F, Squire I, et al. Risk Factors for Heart Failure. 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. Circ Heart Fail. 2020; 13(2): e006472. DOI:10.1161/CIRCHEARTFAILURE.119.006472:e006472
Maddox T, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol. 2021; 77(6):772-810. DOI:10.1016/j.jacc.2020.11.022
Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a populationbased study of 4 million individuals. Lancet. 2018;391(10120):572580. doi:10.1016/S01406736(17)325205.
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics — 2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139e596. doi:10.1161/CIR.0000000000000757
Vasan R.S., Enserro D.M., Beiser A.S., Xanthakis V. Lifetime Risk of Heart Failure Among Participants in the Framingham Study. J Am Coll Cardiol. 2022;79(3):250–263. https://doi.org/10.1016/j.jacc.2021.10.043.
McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.
Remme W.J., Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 2001;22(17):1527–1560. DOI: 10.1053/euhj.2001.2783.
Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8−161. DOI: 10.18087/cardio. 2475
Triposkiadis F., Xanthopoulos A., Parissis J., Butler J., Farmakis D. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail. Rev.2022;27(1):337−344. DOI: 10.1007/s10741-020-09987-z.
Fayol A., Wack M., Livrozet M., Carves J.B., Domengé O., Vermersch E. et al. Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2022;9(1):519−530. DOI: 10.1002/
ehf2.13717
Ройтберг Г.Е., Струтынский А.В. Внутренние болезни.
Сердечно-сосудистая система: учеб. пособие. М.: МЕД-пресс-информ, 2019:904.
Калюжин В.В., Тепляков А.Т., Калюжин О.В. Сердечная недостаточность. М.: Медицинское информационное агентство, 2018:376.
Gheorghiade M., De Luca L., Bonow R.O. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am. J. Cardiol. 2005;96(12A):3L−9L. DOI: 10.1016/j.amjcard.2005.09.059.
Ferrari R., Cardoso J., Fonseca M.C., Aguiar C., Moreira J.I., Fucili A. et al. ARNIs: balancing “the good and the bad” of neuroendocrine response to HF. Clin. Res. Cardiol. 2020;109(5):599−610. DOI: 10.1007/s00392-019-01547-2.
Gu J., Noe A., Chandra P., Al-Fayoumi S., Ligueros-Saylan M., Sarangapani R. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 2010;50(4):401−414. DOI: 10.1177/0091270009343932.
Dobrek Ł., Thor P. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy. Acta Pol.Pharm. 2011;68(3):307−316.
Lin Y., Wu M., Liao B., Pang X., Chen Q., Yuan J. et al. Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials. Front. Pharmacol. 2021;12:707777. DOI: 10.3389/fphar.2021.707777.
Filippatos G., Anker S.D., Agarwal R., Ruilope L.M., Rossing P., Bakris G.L. et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022; 145(6):437−447. DOI: 10.1161/ CIRCULATIONAHA.121.057983
Batool A., Salehi N., Chaudhry S., Cross M., Malkawi A., Siraj A. Role of vasodilator therapy in acute heart failure. Cureus. 2021;13(8):e17126. DOI: 10.7759/cureus.17126.
Urbach J., Goldsmith S.R. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther. Adv. Cardiovasc. Dis. 2021;15:1753944720977741. DOI: 10.1177/1753944720977741.
Cotter G., Davison B.A., Edwards C., Takagi K., Cohen-Solal A., Mebazaa A. Acute heart failure treatment: a light at the end of the tunnel? Eur. J. Heart Fail. 2021;23(5):698−702. DOI: 10.1002/ejhf.2116.
